Elite Pharmaceuticals Inc (ELTP) Q3 2025 Earnings Report

Revenue: $14.364 million; YoY change: −7.56%; QoQ change: −23.92%
Gross Profit: $6.119 million; Gross Margin: 42.60%; YoY Gross Margin change: −8.63%; QoQ: −25.35%
Operating Income: $1.098 million; Operating Margin: 7.64%; YoY: −68.92%; QoQ: −68.50%
Net Income: $(10.892) million; Net Margin: −75.83%; YoY: (extremely negative, driven by non-operating items); QoQ: +1.31%
EPS: $(0.01) per share; EPS Diluted: $(0.01)
EBITDA: $(10.085) million; EBITDA Margin: (−70.21%)
Balance Sheet: total assets $90.76 million; total liabilities $54.31 million; stockholders’ equity $36.45 million
Liquidity: current ratio 3.27; quick ratio 1.90; cash ratio 0.57; cash & equivalents $8.29 million; inventory $20.16 million; accounts receivable $18.45 million
Leverage: total debt $11.18 million; net debt $2.88 million; debt/equity 0.31; debt to capitalization 23.5%
Cash Flow: Net cash provided by operating activities $(1.06) million; free cash flow $(1.06) million; cash at end of period $8.74 million
Capital Deployment: no dividends; no share repurchases in QQ3 2025; capex data not disclosed for the quarter